Codexis (CDXS)
(Delayed Data from NSDQ)
$3.61 USD
-0.16 (-4.24%)
Updated May 17, 2024 04:00 PM ET
After-Market: $3.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Brokerage Reports
Codexis, Inc. [CDXS]
Reports for Purchase
Showing records 1 - 20 ( 46 total )
Company: Codexis, Inc.
Industry: Industrial Services
Digital Biology Tech- Enabled Drug Discovery Initiation
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Codexis, Inc.
Industry: Industrial Services
Company: Codexis, Inc.
Industry: Industrial Services
A Challenging 2023 and an Uncertain Future; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Short-Term Challenges Due to End of Paxlovid Revenues; Long-Term Thesis Intact; Adjust PT to $9; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Refocusing on Pharma Products and Therapeutics; Adjust PT to $15; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Short-Term Impact on R&D Revenue; Long-Term Thesis Unchanged; Lower $25 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Market Uncertainty Hitting Research Revenue; Paxlovid Supply Agreement Secured; Lower $27 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Looking to Revenue Growth and Clinical Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Paxlovid-Related Growth to Continue Into 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Growth Continues in All Segments; Higher $38 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Pfizer Supply Agreement Could Become a Major Growth Driver; Higher $33 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Company: Codexis, Inc.
Industry: Industrial Services
New Enzyme Product Driving Record Revenues; Higher $28 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
2021 Guidance Raised on New Proprietary Enzyme Contract; Higher $27 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Codexis, Inc.
Industry: Industrial Services
New Products Driving Revenue Growth; Expanding Therapeutics Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Strong Revenue Growth Expected in 2021; Higher $26 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Expect Strong 3Q20 to Carry the Momentum; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Codexis, Inc.
Industry: Industrial Services
Strong 2Q20 Sets up for Better 2H20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Expanding Into a New Vertical; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Alphazyme Partnership Leading to New Opportunities; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S